Karim Malek
About
Karim Malek is a scholar working on Oncology, Molecular Biology and Reproductive Medicine.
According to data from OpenAlex, Karim Malek has authored 30 papers receiving a total of 716 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Molecular Biology and 9 papers in Reproductive Medicine. Recurrent topics in Karim Malek's work include Ovarian cancer diagnosis and treatment (9 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (6 papers) and Advanced Breast Cancer Therapies (4 papers). Karim Malek is often cited by papers focused on Ovarian cancer diagnosis and treatment (9 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (6 papers) and Advanced Breast Cancer Therapies (4 papers). Karim Malek collaborates with scholars based in United States, Canada and Spain. Karim Malek's co-authors include Kathleen N. Moore, Michael J. Birrer, Daniel G. Wright, Ignace Vergote, Lainie P. Martin, David M. O’Malley, Antonio González-Martı́n, Lucy Gilbert, Vaishali Sanchorawala and Ursula A. Matulonis and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.
In The Last Decade
Karim Malek
29 papers receiving 708 citations
Peers
Karim Malek
Steve Nicholson United Kingdom
Robert D. Legare United States
Joyce Varughese United States
Kristen J. Pierce United States
Theresa Gilewski United States
Saifee Mullamitha United Kingdom
Saverio Danese Italy
Ásgerður Sverrisdóttir Iceland
Donna Stock-Novack United States
A.B.W. Nethersell United Kingdom
Citations per year, relative to Karim Malek Karim Malek (= 1×)
peers
Steve Nicholson
Countries citing papers authored by Karim Malek
Since
Specialization
Citations
This map shows the geographic impact of Karim Malek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karim Malek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karim Malek more than expected).
Fields of papers citing papers by Karim Malek
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Karim Malek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karim Malek. The network helps show where Karim Malek may publish in the future.
Co-authorship network of co-authors of Karim Malek
This figure shows the co-authorship network connecting the top 25 collaborators of Karim Malek. A scholar is included among the top collaborators of Karim Malek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karim Malek. Karim Malek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Malek, Karim, Balawant Kumar, Rizwan Ahmad, Amar B. Singh, & Marc D. Basson. (2025). Focal adhesion kinase: A promising regulator of colitis-associated healing. World Journal of Gastroenterology. 31(33). 105466–105466.
2.
McKean, Meredith, David H. Aggen, Nehal J. Lakhani, et al.. (2022). Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma.. Journal of Clinical Oncology. 40(16_suppl). TPS3169–TPS3169.
3.
Aggen, David H., Meredith McKean, Nehal J. Lakhani, et al.. (2022). 661 Initial results from a phase 1a/b study of IK-175, an oral AHR inhibitor, as a single agent and in combination with nivolumab in patients with advanced solid tumors and urothelial carcinoma. Regular and Young Investigator Award Abstracts. A692–A692.
4.
Tolcher, Anthony W., Nehal J. Lakhani, Meredith McKean, et al.. (2022). A phase 1, first-in-human study of IK-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS3168–TPS3168.
5.
O’Malley, David M., Ursula A. Matulonis, Michael J. Birrer, et al.. (2020). Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecologic Oncology. 157(2). 379–385.
6.
O’Malley, David M., Ursula A. Matulonis, Michael J. Birrer, et al.. (2019). Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.. Journal of Clinical Oncology. 37(15_suppl). 5520–5520.
7.
Moore, Kathleen N., David M. O’Malley, Ignace Vergote, et al.. (2018). Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecologic Oncology. 151(1). 46–52.
8.
Moore, Kathleen N., Ignace Vergote, Ana Oaknin, et al.. (2018). FORWARD I: A Phase III Study of Mirvetuximab Soravtansine Versus Chemotherapy in Platinum-Resistant Ovarian Cancer. Future Oncology. 14(17). 1669–1678.
9.
Matulonis, Ursula A., Kathleen N. Moore, Lainie P. Martin, et al.. (2018). Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study. Annals of Oncology. 29. viii339–viii339.
10.
Moore, Kathleen N., Ignace Vergote, Ana Oaknin, et al.. (2017). FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer. Annals of Oncology. 28. v353–v353.
11.
Granzotto, Adeline, Aurélie Joubert, Muriel Viau, et al.. (2011). Réponse individuelle aux radiations ionisantes : quel(s) test(s) prédictif(s) choisir ?. Comptes Rendus Biologies. 334(2). 140–157.
12.
Weber, Damien C., et al.. (2011). Simultaneous in-field boost for patients with 1 to 4 brain metastasis/es treated with volumetric modulated arc therapy: a prospective study on quality-of-life. Radiation Oncology. 6(1). 79–79.
13.
Ward, Jennifer E., Karim Malek, Vaishali Sanchorawala, et al.. (2007). Association of acquired von Willebrand syndrome with AL amyloidosis. American Journal of Hematology. 82(5). 363–367.
14.
Seldin, David C., Jennifer J. Anderson, Martha Skinner, et al.. (2006). Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood. 108(12). 3945–3947.
15.
Oran, Betül, Karim Malek, Vaishali Sanchorawala, et al.. (2005). Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplantation. 35(6). 567–575.
16.
Malek, Karim, Aliza K. Fink, Soe Soe Thwin, et al.. (2004). The Relationship Among Physicians’ Specialty, Perceptions of the Risks and Benefits of Adjuvant Tamoxifen Therapy, and Its Recommendation in Older Patients With Breast Cancer. Medical Care. 42(7). 700–706.
17.
Wright, Daniel G., et al.. (2004). Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Leukemia Research. 28(11). 1137–1143.
18.
Andersen, Stacy L., Dellara F. Terry, Marsha Wilcox, et al.. (2004). Cancer in the oldest old. Mechanisms of Ageing and Development. 126(2). 263–267.
19.
Malek, Karim, et al.. (2004). Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Leukemia Research. 28(11). 1125–1136.
20.
Seldin, David C., Jennifer J. Anderson, Vaishali Sanchorawala, et al.. (2004). Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood. 104(6). 1888–1893.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Steve Nicholson Breakdown of academic impact, for papers by Robert D. Legare Breakdown of academic impact, for papers by Joyce Varughese Breakdown of academic impact, for papers by Kristen J. Pierce Breakdown of academic impact, for papers by Theresa Gilewski Breakdown of academic impact, for papers by Saifee Mullamitha Breakdown of academic impact, for papers by Saverio Danese Breakdown of academic impact, for papers by Ásgerður Sverrisdóttir Breakdown of academic impact, for papers by Donna Stock-Novack Breakdown of academic impact, for papers by A.B.W. Nethersell